GlassScriptPhysician profile
Nicole Danielle Ferrante
NPI 1932561438
$5,147.67
in general payments reported to CMS, 2019-2025
20 companies · $960 in 2025
The $960 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $112 · 2022: $163 · 2023: $3,104 · 2024: $810 · 2025: $960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,512 · Food and Beverage: $2,361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,512.24 |
| Food and Beverage | $2,361.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,593.38 | 2022-2024 | Resolution 360 Clip, Exalt Model D |
| Medtronic, INC. | $276.35 | 2022-2025 | Pillcam, Endoflip, Gi Genius |
| Janssen Biotech, INC. | $168.56 | 2021-2025 | Tremfya |
| Fujifilm Healthcare Americas Corporation | $160.00 | 2023-2024 | |
| Janssen Scientific Affairs, LLC | $151.43 | 2025 | Tremfya |
| Abbvie INC. | $119.93 | 2025 | |
| Pentax of America, INC. | $118.00 | 2023 | Inspira |
| Phathom Pharmaceuticals, INC. | $87.51 | 2025 | Voquezna |
| Aimmune Therapeutics, INC. | $86.72 | 2025 | Zenpep |
| Pfizer INC. | $78.02 | 2025 | |
| Celltrion USA INC. | $68.96 | 2025 | Vegzelma |
| Qol Medical, LLC | $42.62 | 2025 | Sucraid |
| Madrigal Pharmaceuticals | $31.81 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $29.97 | 2025 | Iqirvo |
| Conmed Corporation | $28.74 | 2021-2025 | Conmed Biliary |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $28.01 | 2025 | |
| Mauna Kea Technologies, INC. | $21.97 | 2025 | |
| Novo Nordisk INC | $20.82 | 2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.33 | 2025 | Xifaxan |
| Amgen INC. | $15.54 | 2025 | Uplizna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Ferrante listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.